The therapeutic potential of LNA-modified siRNAs: reduction of off-target effects by chemical modification of the siRNA sequence - PubMed (original) (raw)
Review
The therapeutic potential of LNA-modified siRNAs: reduction of off-target effects by chemical modification of the siRNA sequence
Kees Fluiter et al. Methods Mol Biol. 2009.
Abstract
Post-transcriptional gene silencing mediated by double-stranded RNA represents an evolutionarily conserved cellular mechanism. Small dsRNAs, such as microRNAs (miRNAs), are part of the main regulatory mechanisms of gene expression in cells. The possibilities of harnessing this intrinsic natural mechanism of gene silencing for therapeutic applications was opened up by the discovery by Tom Tuschl's team a few years ago that chemically synthesized small 21-mers of double-stranded RNA (small interfering RNA, siRNA) could inhibit gene expression without induction of cellular antiviral-like responses, siRNAs are especially of interest for cancer therapeutics because they allow specific inhibition of mutated oncogenes and other genes that aid and abet the growth of cancer cells. However, recent insights make it clear that siRNA faces some major hurdles before it can be used as a drug. Some of these problems are similar to those associated with classic antisense approaches, such as lack of delivery to specific tissues (other than the liver) or tumors, while other problems are more specific for siRNA, such as stability of the RNA molecules in circulation, off-target effects, interference with the endogenous miRNA machinery, and immune responses toward dsRNA. Chemical modifications of siRNA may help prevent these unwanted side effects. Initial studies show that minimal modifications with locked nucleic acids (LNA) help to reduce most of the unwanted side effects. In this chapter we will explore the limitations and possibilities of LNA-modified siRNA that may be used in future therapeutic applications.
Similar articles
- Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality.
Elmén J, Thonberg H, Ljungberg K, Frieden M, Westergaard M, Xu Y, Wahren B, Liang Z, Ørum H, Koch T, Wahlestedt C. Elmén J, et al. Nucleic Acids Res. 2005 Jan 14;33(1):439-47. doi: 10.1093/nar/gki193. Print 2005. Nucleic Acids Res. 2005. PMID: 15653644 Free PMC article. - Small interfering RNA for experimental cancer therapy.
Tong AW, Zhang YA, Nemunaitis J. Tong AW, et al. Curr Opin Mol Ther. 2005 Apr;7(2):114-24. Curr Opin Mol Ther. 2005. PMID: 15844618 Review. - siRNA-based approaches in cancer therapy.
Devi GR. Devi GR. Cancer Gene Ther. 2006 Sep;13(9):819-29. doi: 10.1038/sj.cgt.7700931. Epub 2006 Jan 20. Cancer Gene Ther. 2006. PMID: 16424918 Review. - siRNA delivery systems for cancer treatment.
Oh YK, Park TG. Oh YK, et al. Adv Drug Deliv Rev. 2009 Aug 10;61(10):850-62. doi: 10.1016/j.addr.2009.04.018. Epub 2009 May 5. Adv Drug Deliv Rev. 2009. PMID: 19422869 Review. - LNA-antisense rivals siRNA for gene silencing.
Jepsen JS, Wengel J. Jepsen JS, et al. Curr Opin Drug Discov Devel. 2004 Mar;7(2):188-94. Curr Opin Drug Discov Devel. 2004. PMID: 15603252 Review.
Cited by
- MicroRNAs and intellectual disability (ID) in Down syndrome, X-linked ID, and Fragile X syndrome.
Siew WH, Tan KL, Babaei MA, Cheah PS, Ling KH. Siew WH, et al. Front Cell Neurosci. 2013 Apr 15;7:41. doi: 10.3389/fncel.2013.00041. eCollection 2013. Front Cell Neurosci. 2013. PMID: 23596395 Free PMC article. - Locked and unlocked nucleosides in functional nucleic acids.
Doessing H, Vester B. Doessing H, et al. Molecules. 2011 May 27;16(6):4511-26. doi: 10.3390/molecules16064511. Molecules. 2011. PMID: 21629180 Free PMC article. - Role of microRNAs in endothelial inflammation and senescence.
Qin B, Yang H, Xiao B. Qin B, et al. Mol Biol Rep. 2012 Apr;39(4):4509-18. doi: 10.1007/s11033-011-1241-0. Epub 2011 Sep 28. Mol Biol Rep. 2012. PMID: 21952822 Review. - Therapeutic siRNA: state of the art.
Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, Liang XJ. Hu B, et al. Signal Transduct Target Ther. 2020 Jun 19;5(1):101. doi: 10.1038/s41392-020-0207-x. Signal Transduct Target Ther. 2020. PMID: 32561705 Free PMC article. Review. - Nucleic acids in human glioma treatment: innovative approaches and recent results.
Catuogno S, Esposito CL, Quintavalle C, Condorelli G, de Franciscis V, Cerchia L. Catuogno S, et al. J Signal Transduct. 2012;2012:735135. doi: 10.1155/2012/735135. Epub 2012 May 21. J Signal Transduct. 2012. PMID: 22685651 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical